The roughly 15 million Americans who got J&J’s vaccine may need a second shot after all.
The New York Times reports Monday Johnson & Johnson plans to ask U.S. regulators this week to authorize a booster shot of its single-shot COVID-19 vaccine.
The Food and Drug Administration’s expert advisory committee is scheduled to meet October 15th to discuss whether to grant emergency use authorization for J&J’s booster shot.
The drug maker declined to comment on the report, saying it has submitted data to U.S. regulators and intends to submit data to other regulators as well.
What made J&J’s vaccine particularly attractive was that unlike the two-shot regimen required by Pfizer-BioNTech and Moderna, it required just one shot.
But last month, J&J said an additional shot two months after the first injection boosted effectiveness to 94%. That compares with 70% protection with the single dose.
The FDA has already authorized Pfizer and BioNTech’s booster dose for certain groups. Moderna submitted its authorization request last month.